TRAW TRAWS PHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, TRAWS PHARMA INC reported revenue of n/a, net income of −$3.05M and diluted EPS of −$0.16; for the fiscal year ended December 2025 revenue was $2.79M, up 1134.5% on the year before.

TRAW annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.79M, gross profit n/a, operating income −$17.9M, net income $9.17M (margin 328.7%), EPS $0.82
• Fiscal year ended Dec 2024: revenue $226K, gross profit n/a, operating income −$142M, net income −$167M (margin -73682.7%), EPS −$35.21
• Fiscal year ended Dec 2023: revenue $226K, gross profit n/a, operating income −$20.3M, net income −$18.9M (margin -8384.1%), EPS −$22.57
• Fiscal year ended Dec 2022: revenue $226K, gross profit n/a, operating income −$19.6M, net income −$19.0M (margin -8391.2%), EPS −$0.91
• Fiscal year ended Dec 2021: revenue $226K, gross profit n/a, operating income −$16.5M, net income −$16.2M (margin -7151.8%), EPS −$0.96

TRAW quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$3.05M, EPS −$0.16
• Quarter ended Mar 31, 2026: revenue n/a, net income −$7.11M, EPS −$0.53
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.44M, EPS −$0.82
• Quarter ended Sep 30, 2025: revenue n/a, net income −$3.96M, EPS −$0.34
• Quarter ended Jun 30, 2025: revenue $2.73M (up 4694.7% year over year), net income −$915K, EPS −$0.11
• Quarter ended Mar 31, 2025: revenue $57.0K (up 1.8% year over year), net income $21.5M, EPS $2.09
• Quarter ended Dec 31, 2024 (from the annual report): revenue $56.0K (up 0.0% year over year), net income −$29.9M, EPS −$7.28
• Quarter ended Sep 30, 2024: revenue $57.0K (up 0.0% year over year), net income −$8.48M, EPS −$1.49
• Quarter ended Jun 30, 2024: revenue $57.0K (up 0.0% year over year), net income −$123M, EPS −$20.52
• Quarter ended Mar 31, 2024: revenue $56.0K (up 0.0% year over year), net income −$4.98M, EPS −$5.92
• Quarter ended Dec 31, 2023 (from the annual report): revenue $56.0K (up 0.0% year over year), net income −$4.18M, EPS −$16.45
• Quarter ended Sep 30, 2023: revenue $57.0K (up 0.0% year over year), net income −$4.74M, EPS −$5.64
• Quarter ended Jun 30, 2023: revenue $57.0K (up 0.0% year over year), net income −$4.25M, EPS −$0.20
• Quarter ended Mar 31, 2023: revenue $56.0K (up 0.0% year over year), net income −$5.78M, EPS −$0.28
• Quarter ended Dec 31, 2022 (from the annual report): revenue $56.0K (up 0.0% year over year), net income −$5.42M, EPS −$0.26
• Quarter ended Sep 30, 2022: revenue $57.0K (up 0.0% year over year), net income −$5.40M, EPS −$0.26
• Quarter ended Jun 30, 2022: revenue $57.0K (up 0.0% year over year), net income −$4.02M, EPS −$0.19
• Quarter ended Mar 31, 2022: revenue $56.0K (up 0.0% year over year), net income −$4.12M, EPS −$0.20
• Quarter ended Dec 31, 2021 (from the annual report): revenue $56.0K, net income −$3.76M, EPS −$0.15
• Quarter ended Sep 30, 2021: revenue $57.0K, net income −$3.45M, EPS −$0.22

TRAW cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$18.2M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$29.8M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$17.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$16.3M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$19.5M, share buybacks n/a

TRAW balance sheet

• Jun 30, 2026: cash n/a, total assets $11.5M, total liabilities $9.78M, shareholders' equity n/a
• Mar 31, 2026: cash n/a, total assets $8.16M, total liabilities $13.5M, shareholders' equity n/a
• Dec 31, 2025: cash n/a, total assets $10.6M, total liabilities $11.2M, shareholders' equity n/a
• Sep 30, 2025: cash n/a, total assets $12.4M, total liabilities $7.90M, shareholders' equity n/a
• Jun 30, 2025: cash n/a, total assets $15.6M, total liabilities $7.36M, shareholders' equity n/a
• Mar 31, 2025: cash n/a, total assets $19.1M, total liabilities $13.1M, shareholders' equity n/a
• Dec 31, 2024: cash n/a, total assets $25.0M, total liabilities $56.6M, shareholders' equity n/a
• Sep 30, 2024: cash n/a, total assets $8.94M, total liabilities $11.0M, shareholders' equity n/a

What is TRAW's revenue?

TRAWS PHARMA INC reported $2.79M of revenue for the fiscal year ended December 2025.

Is TRAW profitable?

No. TRAWS PHARMA INC lost $21.6M over the last four quarters.

What is TRAW's EPS?

Diluted earnings per share over the last four quarters were −$1.85; −$0.16 in the latest quarter.

TRAW ownership and insider trades · All stocks